百利天恒:注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药

智通财经
Aug 06
【百利天恒:注射用BL-M14D1联合免疫治疗一线SCLC全球III期临床完成首例给药】百利天恒公告,公司自主研发的创新生物药BL-M14D1联合PD-L1单抗对比含铂化疗联合PD-L1单抗治疗一线广泛期小细胞肺癌的全球多中心III期临床试验,已于近日完成首例受试者给药。该研究是全球第一个在一线广泛期小细胞肺癌开展的ADC+免疫治疗的III期临床研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10